A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Oct 18, 2017

Astellas Enters into a New Collaborative Research Agreement with TB Alliance to Discover Anti- tuberculosis Drugs

Tokyo, October 18, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has entered into a new collaborative research agreement with TB...

Read more about Astellas Enters into a New Collaborative Research Agreement with TB Alliance to Discover Anti- tuberculosis Drugs
Oct 11, 2017

Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct “JOINUS,” a New Drug Discovery Program Using Drug-Repositioning Compound Library

- Three Japanese pharmaceutical companies collaborate in facilitating drug discovery in Japan through open innovation sharing of compounds developed by the companies-

Tokyo and Osaka, October 11, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka; Headquarters: Tokyo; TSE: 4503; “Astellas” ), Mitsubishi Tanabe Pharma Corporation (President...

Read more about Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct “JOINUS,” a New Drug Discovery Program Using Drug-Repositioning Compound Library
Oct 11, 2017

Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer

Solid Tumor Antibody-Drug Conjugate (ADC) Enfortumab Vedotin to be Evaluated as a Monotherapy in Patients Previously Treated with a Checkpoint Inhibitor

TOKYO and BOTHELL, Wash., October 10, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Seattle Genetics Inc., Inc., (NASDAQ: SGEN) today announced...

Read more about Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
Oct 11, 2017

U.S. FDA Grants Fast Track Designation to Astellas for Development of Gilteritinib in Relapsed or Refractory Acute Myeloid Leukemia

TOKYO – October 11, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) has granted...

Read more about U.S. FDA Grants Fast Track Designation to Astellas for Development of Gilteritinib in Relapsed or Refractory Acute Myeloid Leukemia
Oct 2, 2017

Astellas Announces Status of Acquisition of Own Shares

Read more about Astellas Announces Status of Acquisition of Own Shares
Oct 2, 2017

Astellas and TOA EIYO Announce Co-promotion Agreement for Kiklin® Capsules 250mg and Kiklin® Granules 86.2%

Astellas Pharm Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and TOA EIYO LTD. (President: Atsuo Takahashi, “TOA EIYO”) announced that the companies have entered into...

Read more about Astellas and TOA EIYO Announce Co-promotion Agreement for Kiklin® Capsules 250mg and Kiklin® Granules 86.2%
Sep 14, 2017

Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

Pfizer Contacts: For Media Sally Beatty (212) 733-6566 sally.beatty@pfizer.com For Investors Chuck Triano (212) 733-3901 charles.e.triano@pfizer.com Astellas Contact: For Media Tyler Marciniak...

Read more about Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Sep 13, 2017

U.S. FDA Accepts for Review Astellas’ Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder

If approved, the combination therapy could potentially offer a new treatment option for patients whose overactive bladder symptoms are not adequately controlled on monotherapy

Tokyo, Sept. 12, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) has accepted for...

Read more about U.S. FDA Accepts for Review Astellas’ Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder
Sep 11, 2017

Astellas Submits Supplemental New Drug Application for Approval of Additional Indication of “Linaclotide" for Patients with Chronic Constipation in Japan

Tokyo, September 11, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has submitted a supplemental new drug application for...

Read more about Astellas Submits Supplemental New Drug Application for Approval of Additional Indication of “Linaclotide" for Patients with Chronic Constipation in Japan
Sep 1, 2017

Astellas Announces Status of Acquisition of Own Shares

Read more about Astellas Announces Status of Acquisition of Own Shares
Aug 30, 2017

Repatha® Receives Approval for New 420mg Single-Dose Delivery Option in Japan

TOKYO (August 30, 2017) – Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; President and Representative Director: Steve Sugino, “Amgen Astellas”) and Astellas Pharma Inc. (Headquarters,...

Read more about Repatha® Receives Approval for New 420mg Single-Dose Delivery Option in Japan
Aug 24, 2017

Astellas Announces Personnel Changes and Organizational Changes

Read more about Astellas Announces Personnel Changes and Organizational Changes
Aug 22, 2017

First Patient Dosed in Phase 3 MORPHO Trial Evaluating Gilteritinib as Maintenance Therapy Following Hematopoietic Stem Cell Transplantin Patients with FLT3 Mutation-positive Acute Myeloid Leukemia

TOKYO – August 22, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the first patient was dosed in the registrational Phase 3...

Read more about First Patient Dosed in Phase 3 MORPHO Trial Evaluating Gilteritinib as Maintenance Therapy Following Hematopoietic Stem Cell Transplantin Patients with FLT3 Mutation-positive Acute Myeloid Leukemia
Aug 1, 2017

Astellas Announces Status of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act) Tokyo, August 1, 2017- Astellas Pharma Inc. (TSE: 4503, President and CEO:...

Read more about Astellas Announces Status of Acquisition of Own Shares
Aug 1, 2017

LTL Pharma Succeeds Marketing Approval for “Nivadil® Tablets”, “Solantal® Tablets” and “Lowgan® Tablets”, and is Transferred Distribution Rights in Japan

Tokyo (Japan), August 1, 2017 –LTL Pharma Co., Ltd. (Representative Director, Chairman: Sansei Oka, Representative Director, President: Jiro Mizukawa, “LTL Pharma”) and Astellas Pharma Inc....

Read more about LTL Pharma Succeeds Marketing Approval for “Nivadil® Tablets”, “Solantal® Tablets” and “Lowgan® Tablets”, and is Transferred Distribution Rights in Japan
Jul 31, 2017

Astellas Submits Application for Approval of fidaxomicin for the Treatment of Infectious Enteritis Caused by Clostridium difficile in Japan

Tokyo, July 31, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has submitted an application for marketing approval of...

Read more about Astellas Submits Application for Approval of fidaxomicin for the Treatment of Infectious Enteritis Caused by Clostridium difficile in Japan
Jul 27, 2017

Astellas Announces Wind-Down of Agensys Research Operations

Astellas to Retain Certain Promising Antibody-Drug Conjugate R&D Programs of Agensys

TOKYO, July 27, 2017 — Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that it is winding down its Agensys research operations in Santa...

Read more about Astellas Announces Wind-Down of Agensys Research Operations
Jul 21, 2017

U.S. FDA Grants Orphan-Drug Designation to Astellas for Development of FLT3 Inhibitor Gilteritinib in Acute Myeloid Leukemia

TOKYO – July 20, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) granted...

Read more about U.S. FDA Grants Orphan-Drug Designation to Astellas for Development of FLT3 Inhibitor Gilteritinib in Acute Myeloid Leukemia
Jul 7, 2017

Maruho Succeeds Marketing Approval for Anti-Atopic Dermatitis Agent “Protopic® Ointment” in Japan

Osaka and Tokyo (Japan), July 7, 2017 – Maruho Co., Ltd (“Maruho”, Head Office: Osaka, Japan, President and CEO: Koichi Takagi) and Astellas Pharma Inc. (“Astellas”; Head Office: Tokyo,...

Read more about Maruho Succeeds Marketing Approval for Anti-Atopic Dermatitis Agent “Protopic® Ointment” in Japan
Jul 5, 2017

Astellas Named to FTSE4Good Sustainability Index for the Sixth Consecutive Year

Tokyo, July 5, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has been selected for the sixth consecutive year to be included in the...

Read more about Astellas Named to FTSE4Good Sustainability Index for the Sixth Consecutive Year
Jun 30, 2017

Astellas Submits Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder

Tokyo, June 30, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today the submission of a supplemental New Drug Application (sNDA) to the...

Read more about Astellas Submits Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder
Jun 21, 2017

The Astellas Oncology C³ Prize Competition Returns for a Second Year; Aims to Inspire and Support Innovative Ideas for Cancer Care with $100,000 in Grants

The challenge is open to nearly anyone with a tangible, unique idea to improve cancer care

TOKYO – June 20, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today the launch of the second year of the Astellas C³ Prize, a...

Read more about The Astellas Oncology C³ Prize Competition Returns for a Second Year; Aims to Inspire and Support Innovative Ideas for Cancer Care with $100,000 in Grants
Jun 9, 2017

Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer

- Amendment accelerates anticipated PROSPER top-line results by two years -

TOKYO and NEW YORK, June 9, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Pfizer Inc. (NYSE: PFE) announced today the amendment of the protocol...

Read more about Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer
Jun 5, 2017

Kyoto University and Astellas Inaugurate “Alliance Station” with Aim of Realizing Advanced Medical Treatments

Kyoto and Tokyo, June 5, 2017 - Kyoto University (President: Juichi Yamagiwa) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced the inauguration of...

Read more about Kyoto University and Astellas Inaugurate “Alliance Station” with Aim of Realizing Advanced Medical Treatments
Jun 1, 2017

Astellas Announces Commitments to GHIT Fund Replenishment

Tokyo, June 1, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, ”Astellas”) today announced that it has committed to supporting the Global Health Innovative Technology Fund...

Read more about Astellas Announces Commitments to GHIT Fund Replenishment

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts